Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 4/20 | 0.40 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | DGKA | P23743 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17504761 | 0.94 | FOLH1 (0.42) | FOLH1NAALAD2L3MBTL1DGKAALDH1A1 | |
| SCHEMBL17504782 | 0.91 | L3MBTL1 (0.46) | FOLH1NAALAD2L3MBTL1KMT2ACYP2D6 | |
| SCHEMBL17533548 | 0.81 | DGKA (0.34) | L3MBTL1DGKAALDH1A1ENPP2 | |
| SCHEMBL24180327 | 0.80 | DGKA (0.38) | L3MBTL1DGKAALDH1A1ENPP2TRPV1 | |
| SCHEMBL14199952 | 0.78 | DGKA (0.45) | L3MBTL1KMT2APOLBDGKAALDH1A1 | |
| SCHEMBL23934118 | 0.78 | FOLH1 (0.54) | FOLH1NAALAD2DGKA | |
| SCHEMBL19225239 | 0.78 | DNM1 (0.45) | FOLH1NAALAD2CYP2C19ALDH1A1 | |
| SCHEMBL17504759 | 0.77 | HSD17B10 (0.53) | FOLH1L3MBTL1KMT2APOLBALDH1A1 | |
| SCHEMBL23934124 | 0.75 | FOLH1 (0.51) | FOLH1NAALAD2DGKA | |
| SCHEMBL23934133 | 0.75 | FOLH1 (0.51) | FOLH1NAALAD2DGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544176-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-01-28 | — | — | US | disclosed |
| WO-2016022827-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544176-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | FOLH1, KLK3, DNPEP | FOLH1 1/4885NAALAD2 111/4885L3MBTL1 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.